LAVA Therapeutics N.V. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
LVTX Nasdaq 2830 www.lavatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for LAVA Therapeutics N.V.

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation - May 16th, 2025 5:27 am
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update - May 14th, 2025 5:30 am
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - Apr 16th, 2025 5:30 am
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Mar 28th, 2025 5:30 am
LAVA Announces Evaluation of Strategic Options - Feb 25th, 2025 5:00 am
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - Jan 10th, 2025 6:23 am
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 - Dec 10th, 2024 5:30 am
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 6:00 am
LAVA Reports Second Quarter 2024 Financial Results and Business Update - Aug 20th, 2024 5:30 am